Cenveo (CVO) Refinances Balance of 7.875% Notes
- Yahoo! (YHOO) Tops Q3 EPS by 22c
- Johnson & Johnson (JNJ) CEO Looks to Have 250,000 Doses of Ebola Vaccine Available by May
- Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
- EMC Corp. (EMC) Misses Q3 EPS by 2c; Updates FY14 Outlook
- Pre-Open Stock Movers 10/22: (RGLS) (IRBT) (SIX) (BRCM) Higher; (NSPH) (DDD) (HIMX) (LL) Lower (more...)
Cenveo Corporation, a wholly-owned subsidiary of Cenveo, Inc. (NYSE: CVO), completed the steps necessary to refinance the remainder of its 7.875% senior subordinated notes due 2013 ("7.875% Notes"). The Company received the necessary consents to amend and supplement its existing senior secured credit agreement to, among other things, (i) allow for up to $50 million of a new unsecured loan to be prepaid on substantially similar terms as its currently outstanding 7.875% Notes, and (ii) modify certain financial covenants for increased financial flexibility. Simultaneously, the Company raised an additional $15 million of secured term loans due 2016 ("Additional Term Loan") under its senior secured credit agreement. The Company also announced that it secured a commitment from Macquarie Capital for a $50 million unsecured term loan due 2017 ("Unsecured Loan"), subject to customary terms and conditions. Together with the company's revolving credit facility, proceeds of the Unsecured Loan will be used to fund the redemption of the 7.875% Notes. Lastly, the Company announced that it has initiated a mandatory and irrevocable redemption of the 7.875% Notes. The 7.875% Notes will be repaid at par plus accrued and unpaid interest on January 22, 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boulder Brands (BDBD) Stock Plunges; Cuts Q3, Q4 EPS Expectations
- Oramed Pharma (ORMP) Gains After Reporting Top-Line Data From Phase 2a ORMD-0801 Trial
- Federal-Mogull (FDML) Misses Q3 EPS by 13c
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!